Pamidronate
From Ganfyd
(Redirected from Disodium pamidronate)
rINN: Pamidronate
Other Names
Disodium pamidronate, Aredia Dry Powder®
Pharmacological Information
Pharmacology Images
Web information on Pamidronate
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Wikipedia on Pamidronate (Less technical, ? quality control)
Contents |
Introduction
Clinical Use
Indications
- Paget's disease
- Hypercalcaemia of malignancy
- Osteolytic lesions
- Bone pain
Administration
IV
- up to 90mg in divided doses over 2 to 4 days(hypercalcaemia of malignancy)
Clinical Issues
Contra-indications
Cautions and Interactions
Side effects
- Nausea
- Diarrhoea
- Abdomenal pain and distension
- Flatulence
- Dyspepsia
- In long term use (> 7 years) atypical femoral stem fractures have been associated with alendronate and the potential for decreased bone healing and increasing differential fracture risk is a concern for all bisphosphonates due to their mechanism of action[1]
- Atrial fibrillation (subject to on going analysis by regulatory agencies).
- Uveitis (adjusted relative risk = 1.5, 95% CI 1.3 to 1.7) and scleritis (adjusted relative risk = 1.5, 95% CI 1.3 to 1.7)
- Possibly oesophageal malignancy[2]
Nitrogen-containing bisphosphonates
- Osteonecrosis (of jaw) in dose related association
Nitrogen containing iv bisphosphonates
- Acute phase reaction with
- Fever
- Myalgia
- Influenzae like symptoms
